RESUMO
OBJECTIVE: Mother-to-infant transmission (MIT) is the leading cause of hepatitis B virus (HBV) infections globally. The aim of this international study was to assess the impediments to prevention of (MIT) of HBV. METHODS: A cross-sectional survey was developed by the Federation of the International Societies for Pediatric Gastroenterology, Hepatology and Nutrition. (FISPGHAN) The survey was sent to HBV experts of the 5-member societies of FISPGHAN, and 63 of 91 countries/regions responded. Main outcome measures include percentage of countries having vaccine programs, timing of the first dose of HBV vaccine, availability of HBV vaccine for outborn neonates, payment of HBV vaccine and hepatitis B immune globulin, screening HBV markers during pregnancy, and antivirals to highly infectious pregnant mothers. RESULTS: Among the participating countries/regions, 11% did not implement infant HBV immunization programs. The first dose of vaccine was given >24âhours in 36% of the total countries and 100% of African countries. The recommended birth dose was unavailable for outborn neonates in 45% of the total countries, including 92% of African and 50% of Latin American countries/regions. During pregnancy, 44% countries do not screen maternal viral markers, and 46% do not provide third trimester antiviral therapy for highly viremic pregnant mothers. CONCLUSIONS: Our study demonstrated multiple obstacles to achieving the goal of preventing MIT of HBV. Comprehensive public health programs to enhance vaccine coverage rate, supply HBV vaccine for out-born neonates, screening maternal HBV markers, treating highly viremic pregnant mothers are proposed to overcome these obstacles and achieve the goal of preventing MIT of HBV.
Assuntos
Vacinas contra Hepatite B/administração & dosagem , Hepatite B/prevenção & controle , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Estudos Transversais , Feminino , Saúde Global , Hepatite B/epidemiologia , Hepatite B/imunologia , Hepatite B/transmissão , Vacinas contra Hepatite B/economia , Vacinas contra Hepatite B/imunologia , Vírus da Hepatite B/imunologia , Humanos , Programas de Imunização/economia , Programas de Imunização/estatística & dados numéricos , Lactente , Recém-Nascido , Programas de Rastreamento/estatística & dados numéricos , Gravidez , Complicações Infecciosas na Gravidez/epidemiologia , Complicações Infecciosas na Gravidez/imunologia , Complicações Infecciosas na Gravidez/virologia , Sociedades Médicas , Inquéritos e Questionários , Cobertura Vacinal/estatística & dados numéricosRESUMO
Patient safety improvements demand a complex system-wide effort, involving a wide range of actions in performance improvement, environmental safety and risk management, including infection control, safe use of medicines, equipment safety, safe clinical practice and safe environment of care. Healthcare accreditation is one of the major steps towards improving quality and patient safety. Amongst the several accrediting agencies across the world, the Joint Commission International, (JCI) stands out as the gold standard in healthcare accreditation. The patient safety journey for hospitals like the Apollo Group, formally started with Apollo Hospitals, Delhi becoming the first JCI accredited Hospital in India, in 2005. In the years to come, eight hospitals of the Group also became JCI accredited; taking the number of hospitals accredited by JCI to twenty-three in the country. The National Accreditation Board for Hospitals and Healthcare providers (NABH) was formed thereafter and today nearly three hundred hospitals are accredited by NABH across the country. There is more to patient safety and healthcare quality beyond just accreditation. With a view to further improve patient safety; Apollo Hospitals have taken several initiatives.